Ireland
--:--IST
Clinical Trials in the EU / 2025-523409-13-00
Authorised, recruiting Phase I

A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis

2025-523409-13-00 · tracked via the Priya Life Science EU tracker
Sponsor
Lifordi Immunotherapeutics Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
30/01/2026
Enrollment target
40
Sites
Poland

Condition studied

Moderate to Severe Rheumatoid Arthritis

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523409-13-00 on CTIS ↗ ← All trials in the EU